Upadacitinib Approved for Moderate to Severe Rheumatoid Arthritis - Rheumatology Advisor

Upadacitinib Approved for Moderate to Severe Rheumatoid Arthritis  Rheumatology Advisor

The FDA has approved Rinvoq (upadacitinib), a Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis ...